Focus: Lantern Pharma is a Dallas-based oncology-focused biopharmaceutical company developing personalized cancer therapies, currently in mid-stage clinical development with a portfolio spanning lung, breast, prostate, and hematologic malignancies.
Profile data last refreshed 6h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Lantern Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Lantern Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Lantern Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Lantern Pharma announced that its candidate drug LP-300 has achieved significant interim data results in a study targeting non-small cell lung cancer patients with the L858R mutation. - Bitget
Lantern Pharma announced that its candidate drug LP-300 has achieved significant interim data results in a study targeting non-small cell lung cancer patients with the L858R mutation. Bitget
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor - BioSpace
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor BioSpace
AI cancer-therapy firm Lantern Pharma plans May 15 Q1 results - Stock Titan
AI cancer-therapy firm Lantern Pharma plans May 15 Q1 results Stock Titan
What Lantern Pharma (LTRN) is doing to protect its market share (Trend Weakens) 2026-05-08 - ADD Alert - thelegaladvocate.com
What Lantern Pharma (LTRN) is doing to protect its market share (Trend Weakens) 2026-05-08 - ADD Alert thelegaladvocate.com
What Lantern Pharma (LTRN) is doing to protect its market share (Trend Weakens) 2026-05-08 - Factor ETF Flow - Newser
What Lantern Pharma (LTRN) is doing to protect its market share (Trend Weakens) 2026-05-08 - Factor ETF Flow Newser
What Lantern Pharma (LTRN) is doing to protect its market share (Trend Weakens) 2026-05-08 - Regression Channel - thelegaladvocate.com
What Lantern Pharma (LTRN) is doing to protect its market share (Trend Weakens) 2026-05-08 - Regression Channel thelegaladvocate.com
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors.
Evaluation of Potency and Specificity of Cryptophycin-Loaded Antibody-Drug Conjugates.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo